The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
Open accessAbstract
BACKGROUND: In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current regimens are needed. METHODS: We conducted an open-label, phase 2-3, multicenter, randomized, controlled, noninferiority trial to evaluate the efficacy and safety of three 24-week, all-oral regimens for the treatment of rifampin-resistant tuberculosis. Patients in Belarus, South Africa, and Uzbekistan who were 15 years of age or older and had rifampin-resistant pulmonary tuberculosis were enrolled. In stage 2 of the trial, a 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) was compared with a 9-to-20-month standard-care regimen. The primary outcome was an unfavorable status (a composite of death, treatment failure, treatment discontinuation, loss to follow-up, or recurrence of tuberculosis) at 72 weeks after randomization. The noninferiority margin was 12 percentage points. RESULTS: Recruitment was terminated early. Of 301 patients in stage 2 of the trial, 145, 128, and 90 patients were evaluable in the intention-to-treat, modified intention-to-treat, and per-protocol populations, respectively. In the modified intention-to-treat analysis, 11% of the patients in the BPaLM group and 48% of those in the standard-care group had a primary-outcome event (risk difference, -37 percentage points; 96.6% confidence interval [CI], -53 to -22). In the per-protocol analysis, 4% of the patients in the BPaLM group and 12% of those in the standard-care group had a primary-outcome event (risk difference, -9 percentage points; 96.6% CI, -22 to 4). In the as-treated population, the incidence of adverse events of grade 3 or higher or serious adverse events was lower in the BPaLM group than in the standard-care group (19% vs. 59%). CONCLUSIONS: In patients with rifampin-resistant pulmonary tuberculosis, a 24-week, all-oral regimen was noninferior to the accepted standard-care treatment, and it had a better safety profile. (Funded by Médecins sans Frontières; TB-PRACTECAL ClinicalTrials.gov number, NCT02589782.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901814 · Cited by 1,044
Self-citationFinancial burden for tuberculosis patients in low- and middle-income countries: a systematic review
Tanimura, T., Jaramillo, E., Weil, D., Raviglione, M., & Lönnroth, K. (2014) · European Respiratory Journal · doi:10.1183/09031936.00193413 · Cited by 586
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
Conradie, F., Bagdasaryan, T. R., Borisov, S., Howell, P., Mikiashvili, L., Ngubane, N., Samoilova, A., Skornykova, S., Tudor, E., Variava, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119430 · Cited by 578
Self-citationFour-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Dorman, S. E., Nahid, P., Kurbatova, E. V., Phillips, P. P. J., Bryant, K., Dooley, K. E., Engle, M., Goldberg, S. V., Phan, H. T. T., Hakim, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033400 · Cited by 539
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
Nunn, A. J., Phillips, P. P. J., Meredith, S. K., Chiang, C.-Y., Conradie, F., Dalai, D., van Deun, A., Dat, P.-T., Lan, N., Master, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811867 · Cited by 390
Self-citationMirzayev, F., Viney, K., Linh, N. N., Gonzalez-Angulo, L., Gegia, M., Jaramillo, E., Zignol, M., & Kasaeva, T. (2021) · European Respiratory Journal · doi:10.1183/13993003.03300-2020 · Cited by 301
Lan, Z., Ahmad, N., Baghaei, P., Barkane, L., Benedetti, A., Brode, S. K., Brust, J. C. M., Campbell, J. R., Chang, V. W. L., Falzon, D., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30047-3 · Cited by 268
Principles for designing future regimens for multidrug-resistant tuberculosis
Brigden, G., Nyang’wa, B.-T., du Cros, P., Varaine, F., Hughes, J. A., Rich, M., Horsburgh, C. R., Mitnick, C. D., Nuermberger, E. L., McIlleron, H., et al. (2013) · Bulletin of the World Health Organization · doi:10.2471/blt.13.122028 · Cited by 79
Self-citationA partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
Tweed, C., Wills, G. H., Crook, A. M., Amukoye, E., Balanag, V. M., Ban, A. Y. L., Bateson, A. L. C., Betteridge, M., Brumskine, W., Caoili, J., et al. (2021) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.20.0513 · Cited by 58
Self-citation
Cited by
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis
Reid, M., Agbassi, Y. J. P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01379-x · Cited by 87
Metadata
- Authors
- Nyang’wa, B.-T., Berry, C., Kazounis, E., Motta, I., Parpieva, N., Tigay, Z., Solodovnikova, V., Liverko, I., Moodliar, R., Dodd, M., Ngubane, N., Rassool, M., McHugh, T. D., Spigelman, M., Moore, D. A. J., Ritmeijer, K., du Cros, P., & Fielding, K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-12-22
- Volume
- 387
- Issue
- 25
- Pages
- 2331-2343
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4313214106
- Cited by
- 376
- References
- 13
- FWCI
- 33.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. https://app.cochat.ai/papers/10.1056/nejmoa2117166
- The paper
- Nyang’wa, B.-T., Berry, C., Kazounis, E., Motta, I., Parpieva, N., Tigay, Z., Solodovnikova, V., Liverko, I., Moodliar, R., Dodd, M., Ngubane, N., Rassool, M., McHugh, T. D., Spigelman, M., Moore, D. A. J., Ritmeijer, K., du Cros, P., & Fielding, K. (2022). A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2117166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.